OpenOnco
UA EN

Onco Wiki / Drug

Nicotine transdermal patch

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDDRUG-NICOTINE-PATCH
TypeDrug
Aliases
HabitrolNRT patchNicoDerm CQNicorette patchNicotine replacement therapy — patchNiquitinНікотиновий трансдермальний пластир
Statusreviewed 2026-05-18 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-NCCN-BCELL-2025

Drug Facts

ClassNicotine replacement therapy (NRT) — transdermal nicotine
MechanismDelivers controlled-release nicotine via skin absorption, producing steady plasma levels (~one-third to one-half of typical cigarette smoking) that substantially relieve craving and withdrawal symptoms while avoiding the rapid pulse + peak of inhaled smoking that drives reinforcement. First-line for tobacco cessation per USPSTF / AHCPR; combination with short-acting NRT (lozenge or gum) further improves quit rates vs. monotherapy.
Typical dosingPatch-strength laddered to baseline cigarette exposure: - >10 cig/d: 21 mg/24h × 4-6 weeks, then 14 mg/24h × 2 weeks, then 7 mg/24h × 2 weeks (total 8-10 weeks) - ≤10 cig/d: start at 14 mg/24h Apply to clean, non-hairy upper-body skin; rotate site daily. Patch worn 24 h (or 16 h if vivid dreams problematic). Combination NRT (patch + short-acting lozenge or gum PRN cravings) preferred over monotherapy.
Ukraine registeredTrue
NSZU reimbursedFalse
Ukraine last verified2026-05-18

Notes

STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. First-line tobacco-cessation NRT; USPSTF Grade A. Combination NRT (patch as baseline + lozenge/gum PRN) improves abstinence vs. monotherapy. Safer than continued smoking even in cardiovascular disease — net benefit favors NRT in all but the most unstable cardiac patients. Source cited (SRC-NCCN-BCELL-2025) is closest in-KB until dedicated USPSTF/AHCPR/Cochrane NRT sources land in source-stub workstream.

Used By

Drug

Regimens